Fennec Pharmaceuticals is trading 5.7% down at $11.20 amid a broad biotech-sector pullback.
- Biotech shares fell 2.47% during regular trading.
- No new company-specific announcement, earnings release, regulatory action, or analyst downgrade was identified for August 20, 2026.
- Its August 11 second-quarter report showed $17.1 million in net product sales, up 78% year over year; rising Treasury yields and weaker major indexes added to risk-off sentiment.